Evidence map›Paper›PMID 32485836›Full record

ArticleToxins2020

PLA

Oleksandr Zinenko, Igor Tovstukha, Yevgen Korniyenko

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Toxins, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04996264 (Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of a Multi-Dose Regimen of Oral Varespladib-Methyl in Subjects Bitten by Venomous Snakes), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04996264 phase2completednot on this mapstarted 2021, after this paper: background citation

Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of a Multi-Dose Regimen of Oral Varespladib-Methyl in Subjects Bitten by Venomous Snakes

TypeinterventionalSponsorOphirex, Inc.Ran2021 to 2023Enrolled95ConditionsSnakebites, Envenoming, Envenoming, Snake, Envenomation, SnakeArmsVarespladib Methyl, Placebo, Standard of care (SOC)
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Toxicon: X · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Unraveling snake venom phospholipase APharmacological reports : PR · 2023
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Oleksandr ZinenkoV. N. Karazin Kharkiv University, 61058 Kharkiv, Ukraine.
Igor TovstukhaUkrainian Independent Ecology Institute, 61001 Kharkiv, Ukraine.
Yevgen KorniyenkoV. N. Karazin Kharkiv University, 61058 Kharkiv, Ukraine.
V. N. Karazin Kharkiv National University · UA

Funding

V. N. Karazin Kharkiv National University modernization fund 2017-10
6 · The paper itself

Abstract

Although envenoming by a small East European species of viper is rarely severe, and only exceptionally fatal, lack of specific antivenom stocks in a few areas within this region and possible severe side effects of antivenom application leave most bites to be treated only with antihistamines and supportive therapy. Varespladib is an effective inhibitor of snake phospholipase, and, as such, it could be considered as first-line therapy. The Nikolsky's viper venom contains an extremely high concentration of phospholipase A2 (PLA

Indexed as

ViperidaeAcetatesAnimalsDisease Models, AnimalIndolesKeto AcidsMaleMicePhospholipase A2 InhibitorsPhospholipases A2Snake BitesViper VenomsAcetatesIndolesKeto AcidsPhospholipase A2 InhibitorsPhospholipases A2varespladibViper VenomsinhibitormousePLA2snakebitetherapyVarespladibViperidae

Identifiers

PMID32485836
PMCPMC7354479
OpenAlexW3032722376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.